Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl M Gay

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
JTO Clinical and Research Reports|February 15, 2024
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From <i>EGFR</i>-Mutant NSCLC Informs Potential Therapeutic TargetsBingnan Zhang, Whitney Lewis, C Allison Stewart, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancerMarcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, et al.
Nature Communications|February 8, 2023
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancerLingzhi Hong, Muhammad Aminu, Shenduo Li, et al.
Cancer Discovery|July 18, 2018
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 BlockadeLimo Chen, Lixia Diao, Yongbin Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 12, 2020
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLCLingzhi Hong, Marcelo V Negrao, Seyedeh S Dibaj, et al.
Cancer Cell|January 26, 2024
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypesSimon Heeke, Carl M Gay, Marcos R Estecio, et al.
Nature Communications|November 18, 2021
Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancerMing Chen, Runzhe Chen, Ying Jin, et al.
The Lancet. Digital Health|June 2, 2023
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective studyMaliazurina B Saad, Lingzhi Hong, Muhammad Aminu, et al.
Cell Reports|April 5, 2018
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous CarcinomasJoshua D Campbell, Christina Yau, Reanne Bowlby, et al.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
JTO Clinical and Research Reports|February 15, 2024
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From <i>EGFR</i>-Mutant NSCLC Informs Potential Therapeutic TargetsBingnan Zhang, Whitney Lewis, C Allison Stewart, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancerMarcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, et al.
Nature Communications|February 8, 2023
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancerLingzhi Hong, Muhammad Aminu, Shenduo Li, et al.
Cancer Discovery|July 18, 2018
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 BlockadeLimo Chen, Lixia Diao, Yongbin Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 12, 2020
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLCLingzhi Hong, Marcelo V Negrao, Seyedeh S Dibaj, et al.
Cancer Cell|January 26, 2024
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypesSimon Heeke, Carl M Gay, Marcos R Estecio, et al.
Nature Communications|November 18, 2021
Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancerMing Chen, Runzhe Chen, Ying Jin, et al.
The Lancet. Digital Health|June 2, 2023
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective studyMaliazurina B Saad, Lingzhi Hong, Muhammad Aminu, et al.
Cell Reports|April 5, 2018
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous CarcinomasJoshua D Campbell, Christina Yau, Reanne Bowlby, et al.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Pageof 9